On July 22, 2022, on the occasion of the 19th Congress on Cardiac Imaging and Cardiac Intervention (CICI 2022), presented by Medtronic The Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management, organized, specially invited a number of heavyweight experts in the cardiovascular field and leaders from all walks of life to gather online to face the three lows of hypertension awareness rate, treatment rate and control rate in my country. The clinical needs of hypertensive patients continue to explore innovative treatments through the combination of medicine and industry, change the way of hypertension treatment with innovative treatments, deeply integrate the whole process of hypertension diagnosis and treatment with innovative management, and open up the accessibility of treatments with innovative policies, focusing on the prevention, intervention, diagnosis and treatment of hypertension. The key nodes in the whole process from evaluation to treatment management will contribute to the construction of the national chronic disease prevention and control system and benefit more Chinese patients with hypertension.
The Chinese People’s Liberation Army General Hospital is sincerely invited Professor Chen Yundai, Guangdong Provincial People’s HospitalProfessor Feng Yingqing, Peking University First HospitalProfessor Huo Yong, Peking University People’s HospitalProfessor Sun Ningling strong> served as the chairman of the conference; and invited Huawei Terminal BG Health Solution Chief Architect and Product DirectorMr. Chen Qinsheng , Deputy Bureau of Hainan Boao Lecheng International Medical Tourism Pilot Zone AdministrationChiefMs. Fu Zhu , Vice President of Smart Wearable and Sports Health Product Line Solutions, Huawei Terminal BG BusinessMs. Jiang Ting, JD Health Hospital Cooperation Division General ManagerMs. Jin Fangyi, Peking Union Medical College HospitalShen Zhu Junjie Professor, Senior Business Director of Coronary and Renal Sympathetic Nerve Ablation, Medtronic ChinaMr. Wu Lingxiang< /s pan>Served as a guest speaker; also invited Ruijin Hospital Affiliated to Shanghai Jiaotong University School of MedicineProfessor Xu Jianzhong, Shanghai Tenth People’s Hospital< /span>Professor Zhang Yi co-chaired the conference and led all the participating experts to the academic feast. (In alphabetical order)
Opening speech p>
2022 CICI Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management
Professor Chen Yundai delivered a speech and said that this conference has invited many top academics who have been working in the domestic front line of coronary intervention and blood pressure management for many years. At the same time, there are also representatives from many fields such as innovative digital chronic disease management and wearable device-related enterprises, medical pioneering areas, etc., and in-depth discussions on innovative intervention technologies for hypertension and standardized chronic disease management strategies. At present, my country’s hypertension management is facing the severe dilemma that it is difficult to achieve the standard. How to make an emerging technology quickly enter the stage of promotion, clinical application and primary physician training in a more standardized and standardized form is the current key problem. To this end, I would like to express my heartfelt thanks to all the experts, related enterprises and institutions for their strong support. Let us take advantage of this conference to deeply discuss modern hypertension treatment and management methods, and provide certain assistance for the future development of hypertension prevention and treatment in my country.
Innovative treatment breaks through the predicament of reaching the target
2022 CICI Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management
Hypertension is the No. 1 disease burden in the world, with high prevalence and low disease control rate. Among them, China ranks first in the world in terms of hypertension-related deaths and hypertension At the beginning of the meeting, Professor Xu Jianzhongcombined with the data of “May Blood Pressure Measurement Month”, pointed out that the combined treatment rate Low blood pressure, poor compliance, and lack of attention by young patients are important factors for the low compliance rate in China. Intensified antihypertensive treatment is the main trend of hypertension treatment. Research in China provides evidence for intensive antihypertensive treatment in elderly patients. At the same time, he has made some progress in the field of antihypertensive of traditional Chinese medicine. SubsequentlyProfessor Shen Zhujuncombined with SPYRAL HTN-OFF MED Pilot research, SPYRAL HTN -OFF MED Pivotal study, Global Symplicity Registry and other research results show that RDN can provide long-term, safe, effective and durable antihypertensive effect for patients with poor blood pressure control, which can be regarded as a supplementary treatment measure in addition to lifestyle improvement and drug treatment In the future, the clinical application path should be further clarified to make the RDN operation more standardized and standard, and the RDN diagnosis and treatment process clearer, so as to help patients choose the most appropriate blood pressure control strategy, so as to bring a better diagnosis and treatment experience. Finally, Ms. Fu Zhu elaborated on the current situation of Lecheng as a policy and industrial highland, and the progress of system integration and innovation, and looked forward to the future development direction of Lecheng Pioneer District. He also emphasized that the team of Academician Ge Junbo applied Medtronic’s Symplicity G3 RDN system in Boao Super Hospital, successfully completed the first clinical application of radiofrequency ablation of renal artery sympathetic nerve in my country, and realized the change of hypertension treatment in China from “simple drug treatment” to “minimally invasive”. The advancement of medical technology in interventional therapy.
Roundtable Discussion
2022 CICI Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management
width After the wonderful academic lecture, the participating experts also conducted in-depth discussions on the key and dilemma of hypertension treatment, how innovative treatment can break the predicament of reaching the standard, and how to improve the accessibility of innovative treatment in China. Professor Chen YundaiFirst of all, he pointed out that whether it is from the perspective of model management or technology research and development, blood pressure control is always the last word for hypertension prevention and control. From the perspective of improving the predicament of patients and strengthening the effect of prevention and treatment of hypertension, promoting the development of related technology research and development and the development of prevention and treatment management models will be of great importance to the clinical benefits of hypertension patients in my country. Professor Feng Yingqing said that the low compliance of hypertensive patients requires the development of new hypertension treatment technologies to improve compliance and increase compliance rates , bringing the hope of “spring” to the field of hypertension prevention and treatment. Professor Xu Jianzhong also believes that the development of hypertension prevention and control management and technology must be “two-handed”, and the research and development of new technologies will always be the focus of hypertension. One of the very important links in prevention and treatment, the combined development of the two will be more beneficial to the long-term benefits of hypertensive patients in my country. Professor Shen Zhujun added that in addition to lifestyle changes and drug treatment, innovative medical treatment will definitely benefit hypertensive patients. Further clarify the indications and application paths of RDN, improve patient compliance through Internet technology, and strengthen patient exercise through traditional Chinese medicine fitness activities, so as to more effectively improve the rate of hypertension compliance with a lower incidence of complications. Finally, Mr. Wu Lingxiang said that “focusing, promoting and focusing” is the current focus of promoting the development of RDN therapy in China, that is, focusing on cross-regional , Interdisciplinary exchanges to promote the multi-dimensional and in-depth development of innovative therapies, promote standardized training of clinicians to improve the quality control level of new technologies, and focus on local clinical research in China to accumulate clinical experience and scientific research data with Chinese characteristics. Medtronic hopes to work hand in hand with more clinical experts, government agencies and related industry leaders to break through the predicament of blood pressure compliance.
New ideas for chronic disease management to ensure continuous compliance
2022 CICI Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management
img class=”content_title” height=”300″ layout=”responsive” sizes=”(min-width: 320px) 320px, 100vw” src=”https://mmbiz.qpic.cn/mmbiz_png/YqeuoWjkBH6H55U54Hcbjs3F4HsLiaEeBEzeEv9Ex7JId8QlcLPJqALw7axp2h8oxBnXgSWK1dmiav1RnlozaBQw/640″ img class width=”60Hcbjs3F4HsLiaEeBEzeEv9Ex7JId8QlcLPJqALw7axp2h8oxBnXgSWK1dmiav1RnlozaBQw/640″ img=” content_title” height=”300″ layout=”responsive” sizes=”(min-width: 320px) 320px, 100vw” src=”https://mmbiz.qpic.cn/mmbiz_png/YqeuoWjkBH6H55U54Hcbjs3F4HsLiaEeBxiaXeNvOFJbeLMIibAxoedFLvvnaXdVx6vnSa3beQiczMOibL1N2″ width=”” >Innovation should be integrated into the key nodes in the whole process of hypertension from preventive intervention, diagnosis and evaluation to treatment and management.Professor Zhang Yi strong>In the lecture, it was pointed out that TTR has been proven to be an independent parameter, and every 10% increase in TTR will reduce the incidence of MACE events by 10%-16% , TTR may become the “grasp” of blood pressure control. Combined with the results of SPYRAL HTN-OFF MED Pilot study and Global Symplicity Registry study, it further suggests the advantages of RDN technology in blood pressure control.Sun Ningling Professor elaborated on the advantages and benefits of China’s Internet-based hypertension management model. It is believed that under the guidance of the “Chinese Expert Consensus on Internet Management of Hypertension Outside the Hospital”, China’s “Internet + medical treatment” can To further improve the treatment effect, reduce the treatment cost, improve the treatment experience, do a good job in the last mile of hypertension prevention and control, achieve comprehensive blood pressure compliance, and build a healthy China together. Finally, Mr. Chen QinshengThe industry’s first Hybrid blood pressure measurement technology created by the high-performance micro-pump and PPG sensor based on HUAWEI WATCH D is explained in detail. In the future, with the assistance of wearable devices, wisdom may be realized Blood pressure measurement can reflect the impact of a series of key events on blood pressure, and bring more clinical benefits to the majority of Chinese hypertensive patients.
Roundtable Discussion
2022 CICI Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management
At the end of the meeting, the participating experts focused on new indicators and clinical trends for the evaluation of blood pressure compliance, the needs and benefits of standardized Internet management of hypertension outside the hospital, and the development and future of innovative treatment and digital management of hypertension. and other issues were discussed in depth. Professor Huo Yong pointed out that the future development of hypertension management should take the medical model as a breakthrough point, with the help of the Internet, new hypertension drugs, wearable Emerging technologies such as equipment to establish a more continuous management model is the current general trend of international hypertension management. Professor Sun NinglingFor the out-of-hospital management of hypertension, he further stated that the out-of-hospital management model needs to have the characteristics of simplicity, high accuracy and high interest. Blood pressure measurement, blood pressure compliance and other links make the patient experience better, make it easier for patients to accept out-of-hospital treatment plans, and further strengthen their standardized development and management. Professor Chen Yundai added that TTR, as an independent predictor of blood pressure risk assessment, has unique significance in hypertension management pathways, especially in The clinical benefits of 24/7 control of blood pressure, blood pressure drugs with shorter half-life, and missed doses of drugs are more significant. Therefore, from the perspective of clinical chronic disease management, it is necessary to promote TTR as a new evaluation indicator to help more clinicians deepen their understanding of it. Subsequently, regarding health management, Ms. Jiang Ting said that health management has gradually entered the trend of “active health”, and the future health management model The exploration will be carried out in combination with the auxiliary role of wearable products and monitoring technology as well as the patient’s own initiative to improve the patient’s treatment experience in a more rigorous and practical form. Ms. Jin Fangyi pointed out that the integration methods and elements of different diseases are obviously different, and how to use the support of national policies and clinical experts With the help of the patient’s needs as the center, the application of new technologies and different solution products to integrate online diagnosis and treatment with in-hospital offline diagnosis and treatment, so as to form an overall treatment management plan, will be an issue that needs to be explored in the future. Finally, Mr. Wu LingxiangMr. said that for the management of hypertensive patients, Medtronic In the future, we will continue to make efforts in three aspects: improving “affordability”; continuously developing and optimizing products; and promoting the innovation of hypertension therapy. “Healthy China 2030” will be realized at an early date.
Summary
2022 CICI Roundtable Forum on Innovative Treatment of Hypertension and New Ideas for Chronic Disease Management
“Listening to cutting-edge experts The harmony between sound and technology will bring new ideas for the prevention and treatment of hypertensive diseases by allowing medical treatment and technology to collide again.” This roundtable forum effectively pointed out the key points to solve the current dilemma of hypertension treatment, including how to form a new type of hypertension management model with Chinese characteristics under the cooperation and integration of clinical medicine and industrial technology, how to use wearable devices, Internet and other technologies to help Clinicians can better manage chronic diseases. It is believed that with the cooperation of clinical medicine and engineering, it will open up a new development path for the field of hypertension in my country, escort the grand blueprint of “Healthy China 2030”, and help build a closed-loop management of hypertension.New pattern!
Long press, identify the QR code, and follow